Myelotoxicity from chemotherapy

Seminars in Oncology

Volumn 33, Issue 1, 2006, Pages 74-85

  Daniel, Davey ^a   Crawford, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GROWTH FACTOR; IRON; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; THROMBOPOIETIN; VINCRISTINE;

ANEMIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 32244446694     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.11.003     Document Type: Article

References (77)

1. G.H. Lyman, N.M. Kuderer, O. Agboola The epidemiology and economics of neutropenia in hospitalized cancer patients Data from the University Health System Consortium Blood 98 suppl 2001 432a (pt. 1, abstr 1813)
2. E.A. Chrischilles, B. Link, S. Scott Factors associated with early termination of CHOP, and its association with oveall survival among patients with intermediate-grade non-Hodgkin's lymphoma (NHL) Proc Am Soc Clin Oncol 21 2002 143a (abstr 1539)
3. M. Wilson-Royalty, G. Lawless, C. Palmer Predictors for chemotherapy-related severe of febrile neutropenia A review of the clinical literature J Oncol Pharm Pract 7 2002 141 147
4. G.H. Lyman, D.J. Delgado Risk and timing of hospitalization among patients receiving CHOP-like regimens for intermediate-grade non-Hodgkin's lymphoma Blood 100 suppl 2002 780a (pt. 1, abstr)
5. G.P. Bodey, M. Buckley, Y.S. Sathe Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia Ann Intern Med 64 1966 328 340
6. S. Blackwell, J. Crawford Filgrastim (rmetHuG-CSF) in the chemotherapy setting G. Morsty T.M. Dexter Filgrastim (r-metuG-CSF) in Clinical Practice 1994 Marcel Dekker New York, NY 103 116
7. J.A. Talcott, R. Finberg, R.J. Bayer The medical course of cancer patients with fever ad neutropenia. Clinical identification of a low-risk subgroup at presentation Arch Intern Med 148 1988 2561 2568
8. J. Klastersky, M. Paesmans, E.B. Rubenstein The Multinational Association for Supportive Care in Cancer Risk Index A multinational scoring system for identifying low-risk febrile neutropenic cancer patients J Clin Oncol 18 2000 3038 3051
9. G.H. Lyman, N.M. Kuderer, B. Djulbegovic A meta-analysis of granulocyte colon-stimulating factor (rH-G-CSF) to prevent febrile neutropenia in patients receiving cancer chemotherapy Am J Med 112 2002 406 411
10. C.L. Vogel, M.Z. Wojtukiewicz, R.R. Carroll First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer A multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 2005 1178 1184
11. Crawford J, Dale DC, Htoy S,, et al. Myeloid growth factors in cancer treatment. NCCN Practice Guidelines, Clinical Practice Guidelines in Oncology. v.1.2005. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth. pdf.
12. O.A. Clark, G. Lyman, A.A. Castro Colony stimulating factors for chemotherapy induced febrile neutropenia Cochrane Database of Systemic Reviews 2 2004
13. D.W. Maher, J.L. Graham, M. Green Filgrastim in patients with chemotherapy induced febrile neutropenia A double blind, placebo-controlled trial Ann Intern Med 121 1994 492 501
14. H. Ozer, J.O. Armitage, C.L. Bennett 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors Evidence-based, clinical practice guidelines J Clin Oncol 18 2000 3558 3585
15. Kuderer N, Cosler LE, Crawford J,, et al. Cost and mortality associated with febrile neutropenia in adult cancer patients. Cancer (in press)
16. J. Crawford, H. Ozer, R. Stoller Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 1991 164 170
17. G.H. Lyman, C.G. Lyman, R.A. Sanderson Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy J Natl Cancer Inst 85 1993 488 493
18. L.E. Cosler, E.A. Calhoun, O. Agboola Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy Pharmacotherapy 24 2002 488 489
19. G. Bonadonna, M. Zambetti, P. Valagussa Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer The results of 20 years of follow-up N Engl J Med 332 1995 901 906
20. W.C. Wood, D.R. Budman, A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1994 1253 1259
21. G.H. Lyman, D.C. Dale, J. Crawford Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy A nationwide study of community practices J Clin Oncol 21 2003 4524 4531
22. M.L. Citron, D.A. Berry, C. Cirrincione Randomized trial of dose-dense versus conventionally scheduled and sequential versus combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741 J Clin Oncol 21 2003 1431 1439
23. J.M. Epstein, S.M. Donnelly, J.M. O'Byrne Community experience with filgrastim in diverse nonmyeloid malignancies an open-label phase 4 study J Support Oncol 2 suppl 2 2004 54 55
24. J. Ashley, D. Taylor, A. Houts The experience of chemotherapy-induced neutropenia Quality-of-life interviews with adult cancer patients J Support Oncol 2 suppl 2 2004 66 67
25. E.A. Calhoun, C.H. Chang, E.E. Weshman The impact of chemotherapy delays on quality of life in patients with cancer Blood suppl 2003 749a (pt. 1): (abstr 2763)
26. H. Ludwig, E. Friz Anemia in cancer patients Semin Oncol 25 suppl 7 1998 2 6
27. R.M. Meyer, G.P. Browman, M.L. Samosh Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma J Clin Oncol 13 1995 2386 2393
28. P.J. Barrett-Lee, N.P. Bailey, M.E.R. O'Brien Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy Br J Cancer 82 2000 93 97
29. J.E. Groopman, L.M. Itri Chemotherapy-induced anemia in adults Incidence and treatment J Natl Cancer Inst 91 1999 1616 1634
30. D.H. Henry, R.I. Abels Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia Results of double-blind and open-label follow-up studies Semin Oncol 21 suppl 3 1994 21 28
31. J. Glaspy, R. Bukowski, D. Steinberg Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practices J Clin Oncol 15 1997 1218 1234
32. G.D. Demetri, M. Kris, J. Wade Procrit Study Group Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type Results from a prospective community study J Clin Oncol 16 1998 3412 3425
33. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2001 2875 2882
34. T.J. Littlewood, E. Bajetta, J.W.R. Nortier Effects of eEpoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy Results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
35. I. Quirt, C. Robeson, C.Y. Lau Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are not receiving chemotherapy J Clin Oncol 19 2001 4126 4134
36. J.A. Glaspy, J.S. Jadeja, G. Justice Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Br J Cancer 87 2002 268 276
37. M. Hedenus, M. Adriansson, J.S. Miguel Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies A randomized, double-blind, placebo-controlled study Br J Haematol 122 2003 394 403
38. J. Vansteenkiste, R. Pirker, B. Massuti Double-blind, placebo-controlled, randomized phase trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
39. J. Glaspy, J. Jadeja, G. Justice A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease Cancer 97 2003 1312 1320
40. R.E. Smith, N.S. Tchekmedyian, D. Chan A dose- and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer Br J Cancer 88 2003 1851 1858
41. M. Auerbach, H. Ballard, J.R. Trout Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia A multicenter, open-label, randomized trial J Clin Oncol 22 2004 1301 1307
42. N.J. Vogelzang, W. Breitbart, D. Cella Patient, caregiver, and oncologist perception of cancer-related fatigue Results of a tripart assessment survey Semin Hematol 34 suppl 2 1997 4 12
43. R.S. Hillman, C.A. Finch Red Cell Manual (ed 7). 1996 Davis Philadelphia, PA
44. J. Glaspy, R. Bukowski, D. Steinberg Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practices J Clin Oncol 15 1997 1218 1234
45. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2001 2875 2882
46. G.D. Demetri, M. Kris, J. Wade Procrit Study Group Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type Results from a prospective community study J Clin Oncol 16 1998 3412 3425
47. J. Crawford, D. Cella, C.S. Cleeland Relationship between changes in hemoblobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888 895
48. D. Cella, J. Kallich, A. McDermott The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients Results from five randomized clinical trials Ann Oncol 15 2004 979 986
49. R. Sheffield, S.D. Sullivan, E. Saltiel Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia Ann Pharmacother 31 1997 15 22
50. M. Grogan, G.M. Thomas, I. Melamed The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix Cancer 86 1999 1528 1536
51. D.M. Brizel, R.K. Dodge, R.W. Clough Oxygenation of head and neck cancer; changes during radiotherapy and impact on treatment options Radiother Oncol 53 1998 113 117
52. M.A. Socinski, C. Zhang, J.E. Herndon Combine modality trials of the Cancer and Leukemia Group B in stage III non-small cell lung cancer Analysis of factors influencing survival and toxicity Ann Oncol 15 2004 1033 1041
53. C.M. Glaser, W. Millesi, G.V. Kornek Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx Int J Radiat Oncol Biol Phys 50 2001 705 715
54. R. Pirker, J. Vansteenkiste, J. Gateley A phase III, double-blind, placebo-controlled randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer Eur J Cancer 37 suppl 6 2001 264
55. J. Crawford, F. Robert, M. Perry Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy Proc Am Soc Clin Oncol 22 2003 628 (abstr 2527)
56. B. Leyland-Jones Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 2003 459 460
57. M. Henke Erythropoietin to treat head and neck cancer patient with anaemia undergoing radiotherapy Randomized, double-blind, placebo-controlled trial Lancet 362 2003 1255 1259
58. M. Arcasoy, X. Jiang, Z.A. Haroon Expression of erythropoietin receptor splice variants in human cancer Biochem Biophys Res Comm 307 2003 999 1007
59. M. Arcasoy, K. Amin, A.F. Karayal Functional significance of erythropoietin receptor expression in breast cancer Lab Invest 82 2002 911 918
60. G. Acs, P.J. Zhang, C.M. McGarth Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression Am J Pathol 162 2003 1789 1806
61. J. Bohlius, S. Langensiepen, G. Schwarzer Recombinant human erythropoietin and overall survival in cancer patients Results of a comprehensive meta-analysis J Natl Cancer Inst 97 2005 489 491
62. J.Y. Blay, A. LeCesne, C. Mermet A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy Blood 92 1998 405 410
63. D.M. Surgenor, E.L. Wallace, S.H. Hao Collection and transfusion of blood in the United States, 1982-1988 N Engl J Med 322 1990 1646 1651
64. K.R. Meehan, C.O. Matias, S.S. Rathore Platelet transfusions Utilization and associated costs in a tertiary care hospital Am J Hematol 64 2000 251 256
65. C.A. Schiffer, K.C. Anderson, C.L. Bennett Platelet transfusion for patients with cancer Clinical practice guidelines for the American Society of Clinical Oncology J Clin Oncol 19 2001 1519 1538
66. P. Rebulla, G. Finazzi, F. Marangoni The Gruppo Italiano Malattie Ematologich Maligne dell'Adulto: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia: 10,000/mcL versus 20,000/mcL J Clin Oncol 15 1997 1143 1149
67. J. McCullough Current issues with platelet transfusion in patients with cancer Semin Hematol 37 2000 3 10
68. C. Sanz, C. Freire, I. Alcorta Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support Transfusion 41 2001 762 765
69. D.J. Kuter, L.T. Goodnough, J. Romo Thrombopoietin therapy increases platelet yields in healthy platelet donors Blood 98 2001 1339 1345
70. R.L. Basser, J.E. Rasko, K. Clark Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer Lancet 348 1998 1279 1281
71. S. Vadhan-Raj, C.F. Verschraegen, C. Bueso-Ramos Recombinant human thrombopoetin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer Ann Intern Med 132 2000 364 368
72. Fanucchi, J. Glaspy, J. Crawford Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer ?? N Engl J Med 336 1997 404 409
73. C.A. Schiffer, K. Miller, R.A. Larson A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia Blood 95 2000 2530 2535
74. J. Li, C. Yang, Y. Xia Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood 98 2001 3241 3248
75. I. Tepler, L. Elias, J.W. Smith II A randomized placebo-controlled trial of recombinant huan interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 87 1996 3607 3614
76. J.J. Vredenburgh, A. Hussein, D. Fisher A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer Biol Blood Marrow Transplant 4 1998 134 141
77. S.B. Cantor, L.S. Elting, D.V. Hudson II Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy Cancer 97 2003 3099 3106